{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T01:06:20Z","timestamp":1785632780136,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.eplepsyres.2015.11.012","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T14:23:10Z","timestamp":1448979790000},"page":"62-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate"],"prefix":"10.1016","volume":"119","author":[{"given":"Avirup","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 9","key":"10.1016\/j.eplepsyres.2015.11.012_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","article-title":"Epidemiology of idiopathic generalized epilepsies","volume":"46","author":"Jallon","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2015.11.012_bib0010","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.yebeh.2012.06.024","article-title":"Epidemiology of juvenile myoclonic epilepsy","volume":"28","author":"Camfield","year":"2013","journal-title":"Epilepsy Behav."},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2015.11.012_bib0015","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.yebeh.2012.11.051","article-title":"Consensus on diagnosis and management of JME: from founder's observations to current trends","volume":"28","author":"Kasteleijn-Nolst Trenit\u00e9","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0020","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1111\/j.1528-1167.2007.01222.x","article-title":"Psychiatric comorbidity in epilepsy: a population-based analysis","volume":"48","author":"Tellez-Zenteno","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/14656566.2013.800045","article-title":"Treating myoclonic epilepsy in children: state-of-the-art","volume":"14","author":"Striano","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0030","first-page":"2128","article-title":"Prognosis of juvenile myoclonic epilepsy 45 years after onset: seizure outcome and predictors","volume":"81","author":"Senf","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0035","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1528-1167.2012.03526.x","article-title":"Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25\u201363 years of follow-up","volume":"53","author":"Geithner","year":"2012","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2015.11.012_bib0040","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.yebeh.2013.01.001","article-title":"Management of juvenile myoclonic epilepsy","volume":"28","author":"Crespel","year":"2013","journal-title":"Epilepsy Behav."},{"issue":"Suppl. 9","key":"10.1016\/j.eplepsyres.2015.11.012_bib0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1528-1167.2005.00327.x","article-title":"Evidence-based treatment of idopathic generalized epilepsies with older antiepileptic drugs","volume":"46","author":"Hitiris","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0050","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"Jan (6)","key":"10.1016\/j.eplepsyres.2015.11.012_bib0055","first-page":"1","article-title":"Medicines related to valproate: risk of abnormal pregnancy outcomes","volume":"8","author":"Medicines and Healthcare Products Regulatory Agency","year":"2015","journal-title":"Drug Saf. Update"},{"issue":"Suppl. 2","key":"10.1016\/j.eplepsyres.2015.11.012_bib0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/epi.12175","article-title":"Road to refractory epilepsy: the Glasgow story","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.eplepsyres.2015.11.012_bib0065","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.yebeh.2012.06.036","article-title":"Lifetime prognosis of juvenile myoclonic epilepsy","volume":"28","author":"Baykan","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0070","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0140-6736(12)61455-X","article-title":"Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan","volume":"380","author":"Lin","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eplepsyres.2007.06.003","article-title":"Predictors of pharmacoresistant epilepsy","volume":"75","author":"Hitiris","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/01.wnl.0000343850.85763.9c","article-title":"A lifetime psychiatic history predicts a worse seizure outcome following temporal lobectomy","volume":"72","author":"Kanner","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0085","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1212\/WNL.0b013e3181f25b16","article-title":"Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients","volume":"75","author":"Petrovski","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0090","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/brain\/awl048","article-title":"Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up","volume":"129","author":"Mart\u00ednez-Ju\u00e1rez","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.yebeh.2014.11.017","article-title":"An evaluation of the impact of memory and mood on antiepileptic drug adherence","volume":"43","author":"McAuley","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/adc.2008.144386","article-title":"Changing trends in antiepileptic drug prescribing in girls of child-bearing potential","volume":"94","author":"Ackers","year":"2009","journal-title":"Arch. Dis. Child."},{"issue":"Apr","key":"10.1016\/j.eplepsyres.2015.11.012_bib0105","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in women and girls recommendations from a joint Task Force of ILAE-Commission on European Affairs and European Academy of Neurology (EAN)","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.seizure.2014.08.006","article-title":"Withholding the choice of sodium valproate to young women with generalised epilepsy: are we causing more harm than good?","volume":"24","author":"Mole","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0115","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.seizure.2014.08.004","article-title":"Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME)","volume":"23","author":"Asadi-Pooya","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0120","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalised epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0125","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalised epilepsy with myoclonic seizures","volume":"70","author":"Noachter","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0130","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.seizure.2013.07.006","article-title":"Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy in adults: a prospective, unblinded randomized controlled trial","volume":"22","author":"Machado","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11940-011-0131-z","article-title":"Treatment options in juvenile myoclonic epilepsy","volume":"13","author":"Mantoan","year":"2011","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0140","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1528-1167.2006.00672.x","article-title":"The influence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female","volume":"47","author":"Scharfman","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.11.012_bib0145","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111530070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111530070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:34:42Z","timestamp":1760276082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012111530070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":29,"alternative-id":["S092012111530070X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.11.012","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}